IFNA7
Interferon alpha-7
Also known as: IFN-alphaJ, IFNA-J, IFNA7_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P01567
- Gene
- IFNA7
- Ensembl
- ENSG00000214042
- Chromosome
- 9
- Canonical length
- 189 aa
- Protein class
- Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
Predicted to enable cytokine activity and type I interferon receptor binding activity. Predicted to be involved in several processes, including lymphocyte activation involved in immune response; response to exogenous dsRNA; and type I interferon-mediated signaling pathway. Predicted to be located in extracellular region. Predicted to be active in extracellular space. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
189 residues, UniProt reviewed canonical sequence.
>P01567|IFNA7
1 MARSFSLLMV VLVLSYKSIC SLGCDLPQTH SLRNRRALIL LAQMGRISPF SCLKDRHEFR
61 FPEEEFDGHQ FQKTQAISVL HEMIQQTFNL FSTEDSSAAW EQSLLEKFST ELYQQLNDLE
121 ACVIQEVGVE ETPLMNEDFI LAVRKYFQRI TLYLMEKKYS PCAWEVVRAE IMRSFSFSTN
181 LKKGLRRKDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IFNA7 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.32
- Highest tissue expression
- 0 nTPM
Expression across tissuesHPA
Tissue
- adipose tissue: 0 nTPM
- adrenal gland: 0 nTPM
- amygdala: 0 nTPM
- appendix: 0 nTPM
- basal ganglia: 0 nTPM
- blood vessel: 0 nTPM
Single-cell type
- adipocytes: 0 nCPM
- adrenal cortex cells: 0 nCPM
- adrenal medulla cells: 0 nCPM
- alveolar cells type 1: 0 nCPM
- alveolar cells type 2: 0 nCPM
- astrocytes: 0 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 0.4 nTPM
- white matter: 0.3 nTPM
- basal ganglia: 0.2 nTPM
- amygdala: 0.1 nTPM
- hypothalamus: 0.1 nTPM
- medulla oblongata: 0.1 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD missense Z
- -2.4
- DepMap mean gene effect
- -0.11
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adaptive immune response
- B cell activation involved in immune response
- cell-cell signaling
- cellular response to virus
- defense response to virus
- humoral immune response
- natural killer cell activation involved in immune response
- response to exogenous dsRNA
- response to virus
- T cell activation involved in immune response
- type I interferon-mediated signaling pathway
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IFNA7 as an antibody target. Whether an autoantibody or antibody against IFNA7 could matter depends on whether native IFNA7 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IFNA7 is annotated as secreted, so native IFNA7 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label IFNA7 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...